Mycobacterium Tuberculosis (Mtb) is a pathogenic bacterium that is the causative agent of tuberculosis (TB) that kills more than 1.5 million people worldwide annually. One of the main reasons for this high mortality rate is the evolution of new Mtb strains that are resistant to available antibiotics. Therefore, new therapeutics for TB are in constant demand. It is known that DNA replication enzymes of Mtb and humans are different and this represents a potential target for anti-Mtb drug development.
New drugs for non-replicating Mtb, dormant-like state, are in constant demand 15 . The nonreplicating phase can yield formation of biofilm 16 , therefore inhibitors designed to halt DNA replication can affect the biosynthesis of biofilm 17 . Small-molecules that inhibit biofilm formation were developed as agents that target non-replicating Mycobacteria 18 . Biofilms have been shown to resist penetrability of antibacterial agents 19 . Agents that target DNA replication but can also inhibit biofilm formation could therefore provide new insight into the link between DNA replication and biofilm formation.
A variety of techniques were used to find small molecule inhibitors for DNA replication proteins. A method that combines NMR-fragment screening with an optimization using virtual screening (FBVS) was developed that selects inhibitors for DnaG-type DNA primase 20, 21 . FBVS was found to be an effective method especially for challenging targets such as DNA primase 4, 22 . This method yielded five small molecule inhibitors that target T7 DNA primase through a similar binding mechanism as shown by high field NMR 21 . Herein, we describe a further development of novel small molecule inhibitors that target Mtb DnaG based on the molecules that were found to inhibit T7 DNA primase. Some of these molecules also inhibit Gyr, through binding to common structural features shared by these two enzymes. Derivative molecules were synthesized using medicinal chemistry approaches, two of which were found to inhibit growth of Msmg in planktonic and sessile forms (biofilm), thus offering hope for further drug development against TB.
Results

Small molecules that inhibit T7 DNA primase also inhibit Mtb DnaG
Using FBVS we found five drug-like molecules, derived from indole and 2H-chromene, that inhibit the primase domain of gene 4 protein of bacteriophage T7 (T7 DNA primase) 21 . The precise binding site of the three molecules (one containing 2H-chromene and two containing indole) within the T7 DNA primase was discovered by high field NMR spectroscopy 21 . T7 DNA primase shares high structural homology with bacterial DnaG primases and therefore it was used as a model target for the development of anti-DnaG small-molecule inhibitors 4 . On a DNA template containing the primase recognition site, DnaG catalyzes the synthesis of RNA primers ( Fig. 2a ). The ability of Mtb DnaG to synthesize oligoribonuceoltides in the presence of small molecule inhibitors was examined. The reaction involved incubating the Mtb DnaG with oligonucleotide template (5'-CCGACCCGTCCGTAATACAGAGGTAATTGTCACGGT -3'), each one of the four rNTPs, and [a-32 P]-ATP. The radioactivity labeled RNA products were separated by denaturing gel analysis and visualized on an autoradiogram (Fig. 2a ). The decrease in the radioactive signal strength, which is directly proportional to the amount of synthesized RNA primers, indicates the inhibition of primase activity. Not surprisingly, two of the five inhibitors we found, 3-(2-(ethoxycarbonyl)-5-nitro-1H-indol-3-yl)propanoic acid (Compound 13) and 7-nitro-1H-indole-2-carboxylic acid (Compound 17) that inhibit T7 DNA primase, also inhibit the RNA primer synthesis of Mtb DnaG (Fig. 2b, lanes 13 and 17) .
Few inhibitors for Mtb DnaG cross-interact with Gyr of Mtb (Mtb Gyr)
The compounds found to inhibit DnaG primase were also tested against Mtb Gyr that shares a conserved TOPRIM fold with DNA primase. Two assays, ATP hydrolysis and DNA supercoiling assay were carried out with Mtb Gyr (Fig. 2b ). Upon incubation of Mtb Gyr with DNA and [g-32 P]-ATP a radioactive Pi is formed that remains free in solution after treatment with active charcoal. In the presence of a small-molecule inhibitor the decrease in the amount of 32 Pi, indicating a decrease in ATP hydrolysis by Mtb Gyr, is quantified using a scintillation counter ( Fig. 2b, top panel) .
The effect of small molecule inhibitors on the formation of cleavable-complex species by Mtb
Gyr was also measured. In the presence of ATP and absence of inhibitor the enzyme shows marked DNA relaxation activity characterized by negative supercoiling on pBR322 DNA (Fig.   2b , bottom panel). Inhibition of supercoiling activity is characterized by the appearance of ladder of gel bands (Fig. 2b, bottom Some of the small-molecules (13, 15 and 17) that were found to reduce [ 32 P]-Pi release (ATP hydrolysis) also inhibit supercoiling of pBR322 DNA by Mtb Gyr (Fig. 2c , top-left). Two of the molecules (13 and 17) that were found as best inhibitors for Mtb DnaG and Gyr contained the indole scaffold substituted with carboxyl-containing functional group (carboxylic acid/ester) in position two/three and electron-withdrawing nitrogen group in position five/seven. The higher molecular mass of compound 13 covers larger chemical space with a potential to yield larger binding interface with the protein target, therefore compound 13, was selected as a precursor for further optimizations.
Preparation of library of derivatives for the inhibition of Mtb DnaG, SAR cycles
A library of 49 novel derivatives was synthesized in order to improve inhibition efficacy. Three rounds of optimization led to better pharmacophore (Fig. 3a) . The synthesis of ethyl 3-(3-ethoxy-3-oxopropyl)-1H-indole-2-carboxylate derivatives (3a-g, 3c', 4a, 5a, 6a-g, 6c', 7a, 8a-f, 8c', 9af, 9c') and the N-benzylated derivatives of ethyl 3-(3-ethoxy-3-oxopropyl)-1H-indole-2carboxylate (10a-f, 10c', 11a-f, 11c', 12a-f, 12c', 13a-f and 13c') is depicted in Fig. S1 . The synthesis commenced by Japp-Klingemann condensations of the commercially available aniline derivatives 1a-g, afforded the corresponding diethyl derivatives of phenylhydrazones (2a-g) in moderate to good yields. Subsequent Fischer indole cyclisation of the latter phenylhydrazones (p-toluenesulfonic acid, benzene, reflux) 23 , produced the key indole derivatives (3a-g, 3c') in 15-80% yields. Hydrolysis of the latter diesters under mild basic conditions (0.01M NaOH) gave a mixture of the corresponding dicarboxylic acid derivatives 6a-g, 6c' (Round I, Fig 3a) and mono-carboxylic acid derivatives 8a-f, 8c', 9a-f, 9c' (Round II, Fig. 3a ). Reduction of indole diester 3a using LiAlH4 (THF, 4 o C) produced 3-(5-chloro-2-(hydroxymethyl)-1H-indol-3-yl)
propan-1-ol (4a) in 50% yield, while selective oxidation of the latter di-alcohol 4a using PCC afforded dicarboxaldehyde 5a in 40% yield. Diamide 7a was prepared in two steps from ester 3a (0.01M NaOH then aniline, DCC and HoBt, dry DMF) in 60% yield. Benzylation of compounds 3a-f, 3c' (BnBr, Cs2CO3, DMF) afforded obtaining N-benzylindoles 10a-f, 10c'
(Round III, Fig 3a) in 85-95% yields 24 . Partial hydrolysis of the latter diesters (10a-f, 10c') under mild basic conditions (0.01M NaOH) led to the formation of the corresponding dicarboxylic and mono-carboxylic acids 11a-f, 11c', 12a-f, 12c', 13a-f, and 13c' in low to moderate yields.
The newly synthesized molecules were tested for their ability to inhibit the activities of Mtb DnaG and Gyr (Fig. 3b-c) . Some of the newly added groups (3-CF34-Cl and 2-Cl4-CF3 substituents) were essential for inhibition of primase and Gyr activities ( Fig. 3b -c), whereas other functional groups (carboxaldehyde, amide and alcohol substituents) did not improve inhibition (compounds 4a, 5a, and 7a). Summary of SAR conclusions is presented in Fig. 3d .
For example, a decrease in potency of compounds 6a-g, 6c', 4a, 5a, and 7a was attributed to the absence of carboxyethyl and propanoic acid groups at position 2 and 3, respectively. Schematic representation of the three rounds of optimization, for each specific aniline derivative (1a-d), is shown in Fig. S2 . With the new lead structure (compound 8c and 8d) in hand, additional substituents were added to the indole moiety to further develop the structure-activity relationship for the Group II series. Introduction of a benzyl group in -NH position of indole ring to Group II series of compounds increased potency dramatically (as noted for the resulting Group III series of compounds).
Out of 49 newly synthesized compounds, nine compounds (8c, 8d, 8f, 11c', 12c, 13a, 13b, 13c, 13d) were found to inhibit DnaG primase and Gyr of Mtb 
Some of the inhibitors act to stop proliferation of Mycobacterium smegmatis (Msmg)
Since DnaG and Gyr are essential enzymes for every bacterial cell, it seemed likely that compounds 13c and 13d would also affect the growth of Mycobacteria. Msmg is a nonpathogenic relative of Mtb, often used to test antitubercular agents due to the similar morphological and biochemical properties of these two bacterial species. For example, both enzymes used in this study, DnaG primase as well as GyrB subunit, exhibit more than 80% identity between Mtb and Msmg.
The primase/Gyr inhibitors were screened for inhibition of growth of Msmg mc 2 155 over a time course of 20h at 37° C. The antibacterial activity of compounds 13c and 13d were determined by assaying their minimal inhibitory concentration (MIC) against Msmg. The results are summarized in Fig. 4 . Both compounds inhibited the growth of Msmg in accordance with their inhibition of mycobacterial primase/Gyr. Other compounds that showed inhibition of the two enzymes in vitro had little or no effect against Msmg (Fig. 4 , growth curve, colored blue). The MIC90 of compounds 13c and 13d were 86.6 and 250 µM, respectively ( Table 1 , Fig. 5 ). This value was even better than the effective dose measured for isoniazide (250 µM), a first-line anti-TB drug and a central drug in the common treatment regimens ( Fig. 4a inset-coloured grey and Table 1 ).
Conjugation of molecules with cell penetrating peptide for increased cellular uptake and potency
A major limitation for antibiotics against intracellular pathogens such as M. tuberculosis is the need to cross several biological membranes to access the target site 25 . Furthermore, pathogenic mycobacteria present an intrinsically impermeable thick cell wall, which provides as a robust barrier to most antibiotics 26 . Cellular drug delivery can improve efficacy and potency of hydrophobic molecules (water insoluble) which cannot reach high concentration within the cells.
Therefore, the transport of physiologically active compounds across membranes into target cells can be facilitated by cell-penetrating peptides (CPPs), such as HIV-TAT peptides, and octaarginines [27] [28] [29] . It has been previously reported that arginine rich cell penetrating peptide can efficiently deliver the covalently conjugated small molecules into Mtb 30 . Here we have conjugated the biochemically most active molecule from our series, 13d with two cell penetrating peptides ( Fig. S8 ). Interestingly, the conjugated molecules were found to be >50 fold active against the M. smegmatis mc 2 155, compared to compound 13d alone, with the MIC range of 1.9 -3.9 µM ( Fig. 5 and S5, Table 1 ). Under identical conditions we also evaluated the antibacterial activity of cell penetrating peptides and MIC was found to be 7.8 µM for both peptides ( Table 1 ). Hence the conjugation of compounds with peptide facilitates the cellular uptake of DnaG inhibitors and synergistically potentiates the antibacterial activity.
Inhibition of biofilm formation of Msmg, a phenotype for the inhibition of DNA replication
Previous studies have shown that inhibition of DNA replication affects biofilm formation and stability of preformed biofilm 31 . This link between DNA replication and biofilm formation is likely to be consequential. To determine whether compounds 13c and 13d exert their antibacterial effect on biofilm, cells were treated with each compound and their biofilm phenotypes were assessed as described previously 32 (Fig. 5a ). The second compound, 13d, also inhibited biofilm formation, up to 85 % at its' MIC (250 µM) but was unable to inhibit at half-MIC (125 µM). We also evaluated the effect of peptide conjugated 13d against biofilm formation at their MIC and sub MIC level and found to inhibit biofilm formation up to >99%. In identical conditions the peptides alone were not able to inhibit the biofilm formation in both concentrations. Surprisingly, in identical conditions the standard drug isoniazid reduced biofilm formation up to 65% at MIC and did not inhibit the biofilm formation significantly at sub-MIC level (Fig. 5a ). To further corroborate, the alamar blue cell viability assay was performed and we also counted the CFU from Msmg biofilm suspensions treated with our compounds by plating each sample on the 7H10 agar plate ( Fig.   S5 ).
To evaluate the ability of these molecules to disrupt biofilm or inhibit pre-formed biofilm of Msmg mc 2 155 cells we have added the compounds at their respective MIC and sub-MIC to the four days old biofilm and continued the incubation for additional three days. Interestingly, both compounds 13c and 13d significantly reduced the preformed biofilms at their MIC level up to 69.28% and 48.48%, respectively ( Fig. 5b) . At the sub-MIC concentration compound 13c was not able to eradicate the biofilm, whereas 13d inhibited significantly the biofilm up to 55.0 % as compared to the DMSO control. Surprisingly, peptide conjugated to 13d and peptide alone did not affect the preformed biofilm of Msmg, whereas isoniazid induced the biofilm formation as reported previously 33 .
Discussion
Mtb poses a global health hazard, especially since the emergence of drug-resistant strains.
Therefore, new antibiotics with novel mechanisms of action are needed to enrich the current treatment regimens. The DNA replication machinery represents a multiprotein target with very high potential in antibacterial drug design that has been underexploited thus far. Using FBVS we have discovered five small molecule inhibitors for T7 DNA primase that was used as a model system for DnaG-like primases 21 . Not surprisingly two molecules that inhibit T7 DNA primase were also found to inhibit Mtb DnaG. High field NMR was used to determine the location of the precursor inhibitor (compound 13) in the binding site of T7 DNA primase. Aligning the structure of T7 DNA primase (PDB ID: 1nui) 34 with that of Mtb DnaG (PDB ID: 5w33) 35 provided some insight into the binding site of the precursor molecule (compound 13) within Mtb DnaG ( Fig.   S6a ). A few molecules also inhibit Mtb Gyr, presumably through binding to the conserved TOPRIM fold that Gyr shares with DnaG primase, as suggested after docking to the available structure of Mtb Gyr ( Fig S6) . Since the Toprim fold is the common structural feature between the two enzymes we suggest that this fold might have a role in directing the molecules to their designated binding sites.
Compound 13 that served as a promising inhibitor in the initial screening was chosen as a precursor for optimization. To understand which modifications lead to the increase in potency a systematic set of modifications was performed on this precursor molecule. The effect of each modification was tested by observing the changes in the activities of Mtb DnaG and Gyr. Three rounds of optimizations allowed us to draw SAR conclusions related to the inhibitor scaffold.
A few molecules that were found to inhibit DNA primase also inhibit Gyr. Although the IC50 values determined for each enzyme remained in the micromolar range, some of the molecules were able to effectively inhibit growth of bacterial culture (Msmg), presumably due to a dual mechanism of action (synergistic effect). Overall, the N-benzylation of compounds (3a-g, 3c') gave rise to compounds (13a-f and 13c'), which presented maximum inhibitory activity thus far.
The carbonyl-containing groups in positions 2 and 3 of indole probably act as hydrogen bond acceptors, whereas the N-Bn group can also mediate the π-π stacking interactions with aromatic amino acids present in the predicted binding pocket of Mtb DnaG (e.g. tyr-128, tyr-143, phe-149, phe-157, phe-161) ( Fig. S6 ).
Taken together, the SAR studies demonstrated that a variety of hydrophobic substituents introduced on a phenyl ring of indole were well tolerated, and among them the chloro, trifluoromethyl and nitro moiety were preferred. The substituents at position 1 (N-benzyl) as well as positions 2 and 3 (ester and carboxylic acid respectively) of indole were proven to be important for inhibitory activity. In view of our results, it is rationally presumed that the best inhibitors for Mb DnaG/Gyr (13c and 13d) present a viable template to discover more potent inhibitors, by variations of substituents on the phenyl ring or -NH of indole.
The activity and potency of best analogs 13c and 13d is modulated by tight interactions between the pharmacophore and the targets' amino acid residues
Functional group modifications can change the specificity and binding affinity of the molecule to the target's binding site. Some structural variations in the molecules may allow SAR continuity that results in an increased potency. On the other hand, discontinuity in SAR that markedly reduces the potency of an inhibitor after a small chemical modification is termed "the functional cliff". A demonstration for a functional cliff is presented in Fig. 6 , where three substructures that construct compounds 10c and 10d, and their corresponding analogues 13c and 13d, are defined ( Fig. 6 , region A-blue, region B-red, and region C-green). The compounds 10c and 10d present null biological activity (ability to inhibit DnaG and Gyr from Mtb) although they share similar structure with compounds 13c and 13d (Fig. 3d ). Therefore, we conclude that the addition of 3-CF34-Cl (13c) and 2-Cl4-CF3 (13d) substituents (region B) to compounds 10c and 10d is essential for improving the inhibitory activity against DnaG and Gyr. In addition, introduction of a benzyl group on the pharmacophore (region C) increases the potency of the compounds. Importantly, when the ester group was replaced with a carboxylic acid moiety in CPP conjugates were used as a strategy for increasing intra-bacterial intake of the small molecule inhibitors. Although the peptide alone is toxic to the cells, small molecule conjugate exhibited higher toxicity presumably through additional mechanism mediated by electrostatic interactions with the DNA (Fig. S8 ). More specifically, the small molecule serves to anchor the peptide to the protein target, whereas the peptide itself, due to its positive charge, may prevent interaction of DnaG/Gyr with negatively charged DNA. In addition, inhibition of DNA replication by small molecule conjugates also affects biofilm formation. It is possible that inhibitors that halt DNA replication hamper communication between Msmg cells and inhibit their biofilm formation or even eradicate preformed biofilms. We therefore suggest that our DNA replication inhibitors can target planktonic resistance of Mycobacteria.
Online Materials and Methods
Materials
All chemicals and solvents used for the synthesis and characterization of compounds were purchased from Sigma-Aldrich and Acros, and were of reagent grade without purification or drying before use. Chemicals used for biochemical assays were molecular-biology grade, 
Proteins expression-purification
DnaG primase from Mtb
The DNA sequence encoding DnaG primase from Mtb H37Rv was cloned into pET28 vector.
Escherichia coli BL21 (DE3) cells were transformed with created expression vector, grown in LB medium containing 50 mg/mL kanamycin until OD600 = 0.7 and induced with 0.5 mM IPTG. After induction, the culture was incubated with shaking for 4h at 37°C. Cells were harvested by centrifugation (4700 x g, 15 minutes) and pellet was resuspended in the lysis buffer (50 mM Tris-HCl pH 7.5, 500 mM NaCl, 10% v/v glycerol, and 1 mM dithiothreitol). Lysis was performed using pressure homogenizer. The lysate was clarified by centrifugation (21000 x g, 30 minutes), (TBE). Electrophoresis was performed for 4h at 40 V, and the gel was subsequently stained with ethidium bromide (0.5 mg/ml).
ATPase Norit assay for Mtb Gyr
The standard assay for ATPase measures the formation of Norit-adsorbable 32 
Dilution colony assay (Msmg colonies)
The samples from the previously described procedure (Bacterial growth of Msmg culture) were also used for dilution colony assay as explained in the following text. After two hours of monitoring the bacterial growth in Synergy H1 microplate reader, 3μL of each sample was collected and serially diluted in 1:10 ratio (x10 -1 , x10 -2 ,x10 -3 , x10 -4 ). Then 3 μL of each dilution was transferred onto 7H10+ agar plate and incubated at 30°C for four days or until clear colonies were observed in the positive control sample (sample that didn't contain any inhibitor). 
Inhibition of biofilm formation of Msmg, a phenotype for the inhibition of DNA replication
In silico molecular docking
Molecular docking simulations were performed using AutoDock 4.2 36 
Synthesis of indole derivatives
Scheme for the synthesis of all molecules below is presented in Fig. S1 A. General procedures for the synthesis of compounds (2a-g).
(i) Preparation of benzenediazonium salt derivatives (mixture I). To a well stirred solution of aniline derivatives 1a-g (10 mmol) in 5M aq. HCl (16 ml) at 0°C was added dropwise a cold solution (0-5°C) of sodium nitrite (1.38 g, 20 mmol, 2 equiv.) in 10 ml water. Slow addition rate was kept in order to maintain the reaction temperature at 0°C. The resulting mixture was stirred at 0-5°C for additional 30 min in an ice bath.
(ii) Preparation of 2-(ethoxycarbonyl)cyclopentanone anion (mixture II). A solution of 2-(ethoxycarbonyl)cyclopentanone (2.512 ml, 1.344g, 15 mmol) in ethanol (5 ml) was cooled to 0-5°C. Then, a potassium hydroxide solution (5.040 g, 90 mmol, 6 equiv.) in water (5 ml) previously cooled to 0-5°C was added dropwise over a period of 30 min in order to keep the reaction temperature below 8°C. The white-milky appearance mixture was stirred for further 30 min at 0-5°C.
(iii) Preparation of monoethyl derivatives of phenylhydrazones (mixture I+ mixture II). Ice (50 g) was added to mixture II with stirring at 0-5°C in an ice bath, followed by the addition of mixture I, and stirring continued for 1 h at 50°C. The combined mixtures were brought to room temperature and the pH was subsequently adjusted to 4-5 with 1 M aq. HCl. The mixture was extracted with diethyl ether (50 ml×3) and the combined organic layer was dried over magnesium sulfate and filtered. The volatiles were removed under reduced pressure affording a gummy material (95-100%) that was used without further purification in the next step.
(iv) Preparation of diethyl derivatives of phenylhydrazones (2a-g). Concentrated H2SO4 (2.7 ml, 50.5 mmol, 5.1 equiv.) was added dropwise to a stirred solution of monoethyl derivatives (10 mmol) in absolute ethanol (100 ml). The reaction mixture was then heated to reflux for 3 h at 100°C. Then the ethanol was removed under reduced pressure and the residue was treated with 100 ml of ice water. The aqueous solution was extracted with dichloromethane (3 X 50 ml).
The combined organic layer was dried over magnesium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (ethyl acetate:hexane, 1:4) led to the desired product in 80-95% yield as a yellow/brown solid.
B. General procedures for the synthesis of ethyl 3-(3-ethoxy-3-oxopropyl)-1H-indole-2carboxylate derivatives (3a-g, 3c').
A mixture of p-toluenesulfonic acid (3.800 g, 20 mmol, 4 equiv.) and 100 ml of benzene was refluxed for 2 h at 110°C under azeotropic condition. Subsequently, 5 mmol of diethyl derivatives of phenylhydrazone (2a-g) was added and the mixture refluxed for 24 h before the volatiles were distilled. The mixture was washed with saturated solution of NaHCO3 (2 X 30 ml) and water (30 ml). The crude reaction mixture was extracted with dichloromethane (3 X 30 ml) and then washed with water (3 X 20 ml). The organic layer was dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography using ethyl acetate/hexane (1:9 to 1:6) as eluent producing pale white/yellow solid in 15-80% yield.
C. Synthesis of compound 4a.
Dry THF (20 ml) was added dropwise under N2 atmosphere to an ice-cooled RBF containing LiAlH4 (342 mg, 9.0 mmol, 6 equiv.) at 0°C. After completion of THF addition, conc. H2SO4 (240 µl, 4.5 mmol, 3 equiv.) was added to the reaction mixture and the resulting mixture was left to stir at 0°C for 30 min. To the stirred reaction mixture, compound 3a (1.5 mmol) in dry THF was slowly added within 30 min at 0°C and the resulting mixture was left to stir at room temperature for 2 h. After completion of the reaction, ice was added to the resulting reaction mixture and was filtered. Filter cake was washed with ethyl acetate (3 X 20 ml) and then with water (3 X 10 ml).
The organic phase was collected, dried over magnesium sulfate and filtered. Solvent was removed under vacuum to produce grey solid. The residue was purified by silica gel column chromatography using methanol/dichloromethane (1:19) as eluent led to the final products in 50% yield as grey-white solid.
D. Synthesis of compound 5a.
To the solution of compound 4a (0.05 mmol) in dry DCM (5 ml) was added PCC (32 mg, 0.15 mmol, 3 equiv). The reaction mixture was stirred for 3h at room temperature. After completion of the reaction, powdered MgSO4 was added to the resulting reaction mixture and then anhydrous ether (5 X 5 ml) was added, 5X of reaction solvent. The reaction mixture was then, filtered and concentrated. The residue was purified by silica gel column chromatography using ethyl acetate/hexane (1:4) as eluent led to the desired product in 40% yield as a pale white solid.
E. Synthesis of compound 7a.
HOBt (25mg, 0.16 mmol, 2 equiv.) was added to a stirred solution of compound 6a (0.08 mmole) in dry DMF (10 ml) under N2 atmosphere. Subsequently, solution of aniline (15mg, 0.16 mmol, 2 equiv.) in dry DMF was added to the reaction mixture followed by the addition of DCC (34mg, 0.16 mmol, 2 equiv.) and DIPEA (5% equiv.). The resulting mixture was left to stir at room temperature for 48 h. After completion of the reaction, reaction mixture was washed with 1M HCl (3 X 15 ml) followed by 0.1M Na2CO3 aqueous solution (3 X 20 ml) to quench the reaction. The crude mixture was extracted with ethyl acetate. The organic layer was then washed with brine (3 X 15 ml), dried over magnesium sulfate, filtered, and evaporated to dryness. The residue was purified by silica gel column chromatography (ethyl acetate:hexane, 1:6) as eluent led to compound 7a in 60% yield as a white solid.
F. General procedures for the synthesis of compounds (6a-g, 6c'), (8a-f, 8c'), (9a-f, 9c')
and (11a-f, 11c'), (12a-f, 12c'), (13a-f, 13c') .
Compound 3a-g, 3c' (0.5 mmol) and 10a-f, 10c' (0.5 mmol) were dissolved in 50 ml tetrahydrofuran (THF) and the mixture stirred at room temperature for 1 h. Then a solution of NaOH (0.01M) was added and the reaction stirred at room temperature for 18-24 h. After completion of the reaction, the pH was adjusted to 2-3 using 1M aq. HCl, and the product was extracted with diethyl ether (3 X 20 ml). The combined organic layer was dried over magnesium sulfate, filtered, and evaporated to dryness. The residue was purified by silica gel column chromatography (ethyl acetate/hexane, 1:10 to 1:5) as eluent affording products 6a-g, 6c', 8a-f,   8c', 9a-f, 9c' as well as 11a-f, 11c', 12a-f, 12c' and 13a-f, 13c' in as white solids.
G. General Procedures for the Synthesis of N-benzylated derivatives of ethyl 3-(3-ethoxy-
3-oxopropyl)-1H-indole-2-carboxylate (10a-f, 10c').
A catalytic amount of KI (8 mg, 0.05 mmol) and benzyl bromide (214 mg, 1.25 mmol, 2.5 equiv) were added to stirred solution of compounds 3a-f, 3c' (0.5 mmol) and Cs2CO3 (488 mg, 1.5 mmol, 3 equiv) in DMF (20 ml). The reaction mixture was heated to 60°C for 2 h, and then concentrated under vacuum. The residue was dissolved in EtOAc (25 ml), washed with water (3 X10 ml), dried with anhydrous MgSO4 and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (ethyl acetate/hexane, 1:9) as eluent affording compounds 10a-f and 10c') in high yields (85-95%) as yellow oils.
Preparation of cell penetrating conjugates
The Fmoc based solid phase peptide synthesis strategy was used for the synthesis of TAT The experiment was performed as described in Fig. 2b. d , Scheme of synthesis of derivative compounds based on SAR conclusions. Group 1) a. Electron withdrawing group (e.g., NO2, CF3, Cl) renders phenyl ring less nucleophilic and thus more likely to support activity. Incorporation of electron releasing group (e.g., CH3, OH) hinders activity. b. Bulky groups introduce steric hindrance and decrease activity. c. Indole ring. Five membered nitrogen heterocyclic ring system is essential for activity. d. Free nitrogen is essential for activity. Lone pair located on the nitrogen atom is in resonance, and therefore, it stabilizes the structure. e. Carboxylate ester is essential for activity. Activity is reduced when modified to alcohols, amides, aldehydes but increased upon conversion to acid. Group 2) f.
Carboxyl group is essential. Activity is reduced when modified to ester, alcohols, amides, 
